title: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
abstract: OBJECTIVE
  Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients.
  
  
  METHODS
  We conducted a meta-analysis of all randomized trials that compared 5-FU bolus with 5-FU CI, based on individual data from 1,219 patients, to compare the toxicity of the two schedules of 5-FU administration and to identify predictive factors for toxicity. The toxicities considered were World Health Organization (WHO) grade 3 to 4 anemia, thrombopenia, leukopenia, neutropenia, nausea/vomiting, diarrhea, mucositis, and hand-foot syndrome.
  
  
  RESULTS
  Hematologic toxicity, mainly neutropenia, was more frequent with 5-FU bolus than with 5-FU CI (31% and 4%, respectively; P < .0001). Hand-foot syndrome was less frequent with 5-FU bolus than with 5-FU CI (13% and 34%, respectively; P < .0001). There was no difference between the two treatment groups in terms of other nonhematologic toxicities. Independent prognostic factors were age, sex, and performance status for nonhematologic toxicities, performance status, and treatment for hematologic toxicities, and age, sex, and treatment for hand-foot syndrome.
  
  
  CONCLUSIONS
  Based on a large data set, this study confirmed and quantified the toxicity profile of the two schedules of administration of 5-FU and allowed the identification of clinical predictors of toxicity.
authors.forename: E
authors.initials: E
authors.lastname: Lévy
authors.forename: P
authors.initials: P
authors.lastname: Piedbois
authors.forename: M
authors.initials: M
authors.lastname: Buyse
authors.forename: J P
authors.initials: JP
authors.lastname: Pignon
authors.forename: P
authors.initials: P
authors.lastname: Rougier
authors.forename: L
authors.initials: L
authors.lastname: Ryan
authors.forename: R
authors.initials: R
authors.lastname: Hansen
authors.forename: B
authors.initials: B
authors.lastname: Zee
authors.forename: B
authors.initials: B
authors.lastname: Weinerman
authors.forename: J
authors.initials: J
authors.lastname: Pater
authors.forename: C
authors.initials: C
authors.lastname: Leichman
authors.forename: J
authors.initials: J
authors.lastname: Macdonald
authors.forename: J
authors.initials: J
authors.lastname: Benedetti
authors.forename: J
authors.initials: J
authors.lastname: Lokich
authors.forename: J
authors.initials: J
authors.lastname: Fryer
authors.forename: G
authors.initials: G
authors.lastname: Brufman
authors.forename: R
authors.initials: R
authors.lastname: Isacson
authors.forename: A
authors.initials: A
authors.lastname: Laplanche
authors.forename: E
authors.initials: E
authors.lastname: Quinaux
authors.forename: P
authors.initials: P
authors.lastname: Thirion
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects; D009325:Nausea / Q000139:chemically induced; D011379:Prognosis; D011897:Random Allocation; D015996:Survival Rate
chemical_list: D005472:Fluorouracil